Cargando…
P1505: TOLERABILITY AND SAFETY OF INTRAVENOUS IMMUNOGLOBULINS (5% AND 10%) FOR THE TREATMENT OF PATIENTS WITH SECONDARY IMMUNODEFICIENCIES – FINAL SUBGROUP RESULTS OF A NON-INTERVENTIONAL SAFETY STUDY
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430012/ http://dx.doi.org/10.1097/01.HS9.0000972900.20438.84 |
| _version_ | 1785090851726163968 |
|---|---|
| author | Habier, Angela Debes, Anette Muenster, Uwe |
| author_facet | Habier, Angela Debes, Anette Muenster, Uwe |
| author_sort | Habier, Angela |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430012 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104300122023-08-17 P1505: TOLERABILITY AND SAFETY OF INTRAVENOUS IMMUNOGLOBULINS (5% AND 10%) FOR THE TREATMENT OF PATIENTS WITH SECONDARY IMMUNODEFICIENCIES – FINAL SUBGROUP RESULTS OF A NON-INTERVENTIONAL SAFETY STUDY Habier, Angela Debes, Anette Muenster, Uwe Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430012/ http://dx.doi.org/10.1097/01.HS9.0000972900.20438.84 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Habier, Angela Debes, Anette Muenster, Uwe P1505: TOLERABILITY AND SAFETY OF INTRAVENOUS IMMUNOGLOBULINS (5% AND 10%) FOR THE TREATMENT OF PATIENTS WITH SECONDARY IMMUNODEFICIENCIES – FINAL SUBGROUP RESULTS OF A NON-INTERVENTIONAL SAFETY STUDY |
| title | P1505: TOLERABILITY AND SAFETY OF INTRAVENOUS IMMUNOGLOBULINS (5% AND 10%) FOR THE TREATMENT OF PATIENTS WITH SECONDARY IMMUNODEFICIENCIES – FINAL SUBGROUP RESULTS OF A NON-INTERVENTIONAL SAFETY STUDY |
| title_full | P1505: TOLERABILITY AND SAFETY OF INTRAVENOUS IMMUNOGLOBULINS (5% AND 10%) FOR THE TREATMENT OF PATIENTS WITH SECONDARY IMMUNODEFICIENCIES – FINAL SUBGROUP RESULTS OF A NON-INTERVENTIONAL SAFETY STUDY |
| title_fullStr | P1505: TOLERABILITY AND SAFETY OF INTRAVENOUS IMMUNOGLOBULINS (5% AND 10%) FOR THE TREATMENT OF PATIENTS WITH SECONDARY IMMUNODEFICIENCIES – FINAL SUBGROUP RESULTS OF A NON-INTERVENTIONAL SAFETY STUDY |
| title_full_unstemmed | P1505: TOLERABILITY AND SAFETY OF INTRAVENOUS IMMUNOGLOBULINS (5% AND 10%) FOR THE TREATMENT OF PATIENTS WITH SECONDARY IMMUNODEFICIENCIES – FINAL SUBGROUP RESULTS OF A NON-INTERVENTIONAL SAFETY STUDY |
| title_short | P1505: TOLERABILITY AND SAFETY OF INTRAVENOUS IMMUNOGLOBULINS (5% AND 10%) FOR THE TREATMENT OF PATIENTS WITH SECONDARY IMMUNODEFICIENCIES – FINAL SUBGROUP RESULTS OF A NON-INTERVENTIONAL SAFETY STUDY |
| title_sort | p1505: tolerability and safety of intravenous immunoglobulins (5% and 10%) for the treatment of patients with secondary immunodeficiencies – final subgroup results of a non-interventional safety study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430012/ http://dx.doi.org/10.1097/01.HS9.0000972900.20438.84 |
| work_keys_str_mv | AT habierangela p1505tolerabilityandsafetyofintravenousimmunoglobulins5and10forthetreatmentofpatientswithsecondaryimmunodeficienciesfinalsubgroupresultsofanoninterventionalsafetystudy AT debesanette p1505tolerabilityandsafetyofintravenousimmunoglobulins5and10forthetreatmentofpatientswithsecondaryimmunodeficienciesfinalsubgroupresultsofanoninterventionalsafetystudy AT muensteruwe p1505tolerabilityandsafetyofintravenousimmunoglobulins5and10forthetreatmentofpatientswithsecondaryimmunodeficienciesfinalsubgroupresultsofanoninterventionalsafetystudy |